Join Growin Stock Community!

Johnson & johnsonJNJ.US Overview

US StockHealthcare
(No presentation for JNJ)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

JNJ AI Insights

JNJ Overall Performance

JNJ AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

JNJ Recent Performance

0.05%

Johnson & johnson

0.05%

Avg of Sector

-0.31%

S&P500

JNJ PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

JNJ Key Information

JNJ Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

JNJ Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Price of JNJ

JNJ FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

JNJ Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
11.12
PE Ratio (TTM)
22.52
Forward PE
22.43
PS Ratio (TTM)
6.36
PB Ratio
7.20
Price-to-FCF
30.41
METRIC
VALUE
vs. INDUSTRY
Gross Margin
67.88%
Net Margin
28.46%
Revenue Growth (YoY)
6.05%
Profit Growth (YoY)
4.22%
3-Year Revenue Growth
1.19%
3-Year Profit Growth
1.35%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
11.12
PE Ratio (TTM)
22.52
Forward PE
22.43
PS Ratio (TTM)
6.36
PB Ratio
7.20
Price-to-FCF
30.41
Gross Margin
67.88%
Net Margin
28.46%
Revenue Growth (YoY)
6.05%
Profit Growth (YoY)
4.22%
3-Year Revenue Growth
1.19%
3-Year Profit Growth
1.35%

  • When is JNJ's latest earnings report released?

    The most recent financial report for Johnson & johnson (JNJ) covers the period of 2025Q4 and was published on 2025/12/28. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating JNJ's short-term business performance and financial health. For the latest updates on JNJ's earnings releases, visit this page regularly.

  • Where does JNJ fall in the P/E River chart?

    According to historical valuation range analysis, Johnson & johnson (JNJ)'s current price-to-earnings (P/E) ratio is 21.66, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of JNJ?

    According to the latest financial report, Johnson & johnson (JNJ) reported an Operating Profit of 5.43B with an Operating Margin of 22.09% this period, representing a growth of 51.48% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is JNJ's revenue growth?

    In the latest financial report, Johnson & johnson (JNJ) announced revenue of 24.56B, with a Year-Over-Year growth rate of 9.08%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does JNJ have?

    As of the end of the reporting period, Johnson & johnson (JNJ) had total debt of 47.93B, with a debt ratio of 0.24. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does JNJ have?

    At the end of the period, Johnson & johnson (JNJ) held Total Cash and Cash Equivalents of 19.71B, accounting for 0.1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does JNJ go with three margins increasing?

    In the latest report, Johnson & johnson (JNJ) achieved the “three margins increasing” benchmark, with a gross margin of 67.6%%, operating margin of 22.09%%, and net margin of 20.8%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess JNJ's profit trajectory and future growth potential.

  • Is JNJ's EPS continuing to grow?

    According to the past four quarterly reports, Johnson & johnson (JNJ)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 2.12. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of JNJ?

    Johnson & johnson (JNJ)'s Free Cash Flow (FCF) for the period is 5.47B, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 1.88% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of JNJ?

    The latest valuation data shows Johnson & johnson (JNJ) has a Price-To-Earnings (PE) ratio of 21.66 and a Price/Earnings-To-Growth (PEG) ratio of -0.25. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.